Johnson & Johnson (JNJ) Revenue (2009 - 2026)
Johnson & Johnson (JNJ) posted Revenue of $25.3 billion for Q2 2026, up 5.19% sequentially from $24.1 billion in Q1 2026, and up 6.6% YoY from $23.7 billion in Q2 2025.
Johnson & Johnson (JNJ) Revenue (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Revenue for 18 years, with the latest figure at $25.3 billion in Q2 2026.
- Quarterly Revenue rose 6.6% year-over-year to $25.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $97.9 billion (up 8.06% YoY) and the FY2025 annual result came in at $94.2 billion, up 6.05% from the prior year.
- Revenue improved to $25.3 billion in Q2 2026 per JNJ's latest filing, from $24.1 billion in the prior quarter.
- Over five years, Revenue peaked at $25.3 billion in Q2 2026 and troughed at $19.8 billion in Q2 2022.
- A 5-year average of $22.1 billion and a median of $21.7 billion in 2023 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2026: Revenue declined 14.32% in 2022, then climbed 9.91% in 2026.
- Over 5 years, Revenue stood at $20.0 billion in 2022, then climbed by 7.0% to $21.4 billion in 2023, then rose by 5.26% to $22.5 billion in 2024, then rose by 9.08% to $24.6 billion in 2025, then advanced by 3.04% to $25.3 billion in 2026.
- According to Business Quant data, Revenue over the past three periods registered $25.3 billion, $24.1 billion, and $24.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 25.31 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 16.99 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 16.61 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 14.41 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 15.38 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 10.05 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 7.80 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 15.03 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.28 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 13.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 25.31 Bn |
| Mar 29, 2026 | 24.06 Bn |
| Dec 28, 2025 | 24.56 Bn |
| Sep 28, 2025 | 23.99 Bn |
| Jun 29, 2025 | 23.74 Bn |
| Mar 30, 2025 | 21.89 Bn |
| Dec 29, 2024 | 22.52 Bn |
| Sep 29, 2024 | 22.47 Bn |
| Jun 30, 2024 | 22.45 Bn |
| Mar 31, 2024 | 21.38 Bn |
| Dec 31, 2023 | 21.40 Bn |
| Oct 1, 2023 | 21.35 Bn |
| Jul 2, 2023 | 21.52 Bn |
| Apr 2, 2023 | 20.89 Bn |
| Jan 1, 2023 | 19.94 Bn |
| Oct 2, 2022 | 20.00 Bn |
| Jul 3, 2022 | 20.22 Bn |
| Apr 3, 2022 | 19.84 Bn |
| Oct 3, 2021 | 23.34 Bn |
| Jul 4, 2021 | 23.31 Bn |